Andrew Berens
Stock Analyst at Leerink Partners
(1.92)
# 2,762
Out of 4,670 analysts
136
Total ratings
50.98%
Success rate
-5.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZYME Zymeworks | Upgrades: Outperform | $10 → $25 | $14.29 | +74.95% | 10 | Nov 7, 2024 | |
| GILD Gilead Sciences | Upgrades: Outperform | $74 → $96 | $90.19 | +6.44% | 1 | Oct 21, 2024 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $55.68 | +0.57% | 11 | Sep 27, 2024 | |
| VIRX Viracta Therapeutics | Downgrades: Market Perform | $5 → $3 | $0.16 | +1,766.83% | 5 | Aug 16, 2024 | |
| CELC Celcuity | Initiates: Outperform | $29 | $13.19 | +119.86% | 1 | Jul 22, 2024 | |
| BPMC Blueprint Medicines | Upgrades: Market Perform | $50 → $97 | $94.15 | +3.03% | 24 | May 6, 2024 | |
| NUVL Nuvalent | Upgrades: Outperform | $69 → $110 | $94.93 | +15.87% | 1 | Apr 1, 2024 | |
| INCY Incyte | Upgrades: Outperform | $78 | $71.72 | +8.76% | 12 | Dec 13, 2023 | |
| ELEV Elevation Oncology | Upgrades: Outperform | $5 → $8 | $0.60 | +1,225.82% | 4 | May 30, 2023 | |
| MRUS Merus | Maintains: Outperform | $35 → $48 | $45.49 | +5.52% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $236 → $300 | $190.51 | +57.47% | 11 | Jan 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $9.13 | +119.06% | 4 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $22.05 | +26.98% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $74 → $70 | $25.86 | +170.69% | 5 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $79 | $65.63 | +20.37% | 12 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $3.23 | +735.91% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $2.15 | +1,295.35% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $36 → $25 | $12.54 | +99.36% | 3 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $11 | $1.49 | +638.26% | 2 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $8.95 | +346.93% | 1 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $67 | $4.25 | +1,476.47% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $8.49 | +135.57% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $3.92 | +537.76% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $8.83 | -9.40% | 7 | Jul 14, 2017 |
Zymeworks
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $14.29
Upside: +74.95%
Gilead Sciences
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $90.19
Upside: +6.44%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $55.68
Upside: +0.57%
Viracta Therapeutics
Aug 16, 2024
Downgrades: Market Perform
Price Target: $5 → $3
Current: $0.16
Upside: +1,766.83%
Celcuity
Jul 22, 2024
Initiates: Outperform
Price Target: $29
Current: $13.19
Upside: +119.86%
Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50 → $97
Current: $94.15
Upside: +3.03%
Nuvalent
Apr 1, 2024
Upgrades: Outperform
Price Target: $69 → $110
Current: $94.93
Upside: +15.87%
Incyte
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $71.72
Upside: +8.76%
Elevation Oncology
May 30, 2023
Upgrades: Outperform
Price Target: $5 → $8
Current: $0.60
Upside: +1,225.82%
Merus
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $45.49
Upside: +5.52%
Jan 20, 2023
Maintains: Outperform
Price Target: $236 → $300
Current: $190.51
Upside: +57.47%
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $9.13
Upside: +119.06%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $22.05
Upside: +26.98%
Nov 23, 2022
Maintains: Outperform
Price Target: $74 → $70
Current: $25.86
Upside: +170.69%
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $65.63
Upside: +20.37%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $3.23
Upside: +735.91%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $2.15
Upside: +1,295.35%
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $12.54
Upside: +99.36%
May 5, 2022
Maintains: Outperform
Price Target: $9 → $11
Current: $1.49
Upside: +638.26%
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $8.95
Upside: +346.93%
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $4.25
Upside: +1,476.47%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $8.49
Upside: +135.57%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $3.92
Upside: +537.76%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $8.83
Upside: -9.40%